Title:
CXCR4-BINDING COMPOUND OR SALT THEREOF, OR COMPLEX OF SAME AND METAL
Document Type and Number:
WIPO Patent Application WO/2020/009093
Kind Code:
A1
Abstract:
Provided are: a CXCR4-binding compound having high accumulation in tumors that express CXCR4; and a treatment agent for diagnosis or therapy, etc., having the compound as an active ingredient. A compound represented by general formula (1) (the symbols in the formula are set forth in the description), a salt thereof, or a complex of the same and a metal.
Inventors:
SUZUKI KENTARO (JP)
Application Number:
PCT/JP2019/026234
Publication Date:
January 09, 2020
Filing Date:
July 02, 2019
Export Citation:
Assignee:
FUJIFILM TOYAMA CHEMICAL CO LTD (JP)
International Classes:
C07K7/54; A61K38/08; A61K47/42; A61K47/64; A61K51/08; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| WO2015185162A1 | 2015-12-10 | |||
| WO2019050564A1 | 2019-03-14 |
Foreign References:
| JP2010529957A | 2010-09-02 | |||
| JP2010536938A | 2010-12-02 | |||
| CN109517039A | 2019-03-26 |
Other References:
POSCHENRIEDER, ANDREAS ET AL.: "The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity", EJNMMI RESEARCH, vol. 6, no. 36, 2016, pages 1 - 8, XP055388769
POTY,SOPHIE ET AL.: "AMD3100:A Versatile Platform for CXCR4 Targeting 68Ga-Based Radiopharmaceuticals", BIOCONJUGATE CHEMISTRY, vol. 27, 2016, pages 752 - 761, XP055673370
SUZUKI, KNETARO ET AL.: "Synthesis and biological evaluation of a DOTA-conjugated CXCR4 antagonist designed for the imaging and targeted radionuclide therapy of CXCR4-positive tumors", ABSTRACTS OF ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 139, March 2019 (2019-03-01), pages 286
POTY,SOPHIE ET AL.: "AMD3100:A Versatile Platform for CXCR4 Targeting 68Ga-Based Radiopharmaceuticals", BIOCONJUGATE CHEMISTRY, vol. 27, 2016, pages 752 - 761, XP055673370
SUZUKI, KNETARO ET AL.: "Synthesis and biological evaluation of a DOTA-conjugated CXCR4 antagonist designed for the imaging and targeted radionuclide therapy of CXCR4-positive tumors", ABSTRACTS OF ANNUAL MEETING OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 139, March 2019 (2019-03-01), pages 286
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF:
Previous Patent: HEAD-UP DISPLAY
Next Patent: GENERATION DEVICE, GENERATION METHOD, AND GENERATION PROGRAM
Next Patent: GENERATION DEVICE, GENERATION METHOD, AND GENERATION PROGRAM